Skip to main content
海昇药业 logo

海昇药业 — Investor Relations & Filings

Ticker · 920656 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 271 across all filing types
Latest filing 2025-07-03 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920656

About 海昇药业

https://www.zcpc.net/

Zhejiang Haisheng Pharmaceutical Co., Ltd. specializes in the research, development, production, and sale of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The company's core product portfolio includes antipyretic and analgesic medications, cardiovascular agents, and various specialty chemical intermediates. It is recognized as a major global supplier of Naproxen and Naproxen Sodium. Haisheng Pharmaceutical maintains rigorous quality control systems compliant with international standards, including Good Manufacturing Practice (GMP) certifications. The company serves a diverse global clientele, providing high-purity chemical components essential for finished dosage form manufacturing. Its technical expertise focuses on chemical synthesis and process optimization to ensure stable supply chains for the pharmaceutical industry.

Recent filings

Filing Released Lang Actions
浙江海昇药业股份有限公司董事换届公告
Board/Management Information Classification · 95% confidence The document is titled '董事换届公告' which translates to 'Board Re-election Announcement' or 'Board Reshuffle Announcement'. It details the nomination and appointment of new board members, their qualifications, and compliance with relevant laws and regulations. There is no financial data, earnings information, or report publication mentioned. The content focuses on changes in the company's board of directors. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under 'Board/Management Information' (MANG). The document length is 2704 characters, which is relatively short but contains substantive information about board changes, not just a notice or announcement of a report. Therefore, the correct classification is MANG with high confidence.
2025-07-03 Chinese
投资者关系管理制度
Governance Information Classification · 95% confidence The document is titled '投资者关系管理制度' which translates to 'Investor Relations Management System'. It outlines the company's policies and procedures for managing investor relations, including principles, responsibilities, communication methods, and compliance with laws and regulations. There are no financial statements, earnings data, or audit information present. The document is a governance-related policy document rather than a report or announcement of financial results or corporate actions. It is not a report publication announcement since it contains substantive content rather than a brief notice. Therefore, the document fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-07-03 Chinese
年报信息披露重大差错责任追究制度重大信息内部报告制度
Governance Information Classification · 95% confidence The document is titled '年报信息披露重大差错责任追究制度' which translates to 'Annual Report Information Disclosure Major Error Responsibility Pursuit System'. It details the company's internal policy and procedures for handling major errors in annual report disclosures, including definitions, standards for identifying major errors, responsibility and accountability mechanisms, and procedural rules. It does not contain actual financial data or the annual report itself but rather a governance and compliance policy related to annual report disclosures. The document length is 4083 characters, relatively short and focused on internal rules rather than financial results or audit findings. Therefore, it is not the annual report (10-K) itself, nor an audit report (AR), but a governance-related document about annual report disclosure responsibilities. This fits best under Governance Information (CGR), which covers internal rules, board structure, and governance practices related to reporting and disclosures.
2025-07-03 Chinese
关于完成工商变更登记并取得营业执照的公告
Share Issue/Capital Change Classification · 95% confidence The document is a short announcement (518 characters) regarding the completion of a business registration change and obtaining a new business license. It mentions a shareholder meeting decision to amend the company charter and the increase in registered capital. There are no financial statements, detailed financial data, or comprehensive reports included. The document serves as a formal notification of a capital change and registration update rather than a full report or detailed financial disclosure. Therefore, it fits best under the category of Share Issue/Capital Change (SHA).
2025-07-03 Chinese
公司章程
Governance Information Classification · 95% confidence The document is titled as the "章程" (Articles of Association or Company Bylaws) of Zhejiang Chemsyn Pharm Co., Ltd. It contains detailed provisions about the company's organization, shareholder rights, board structure, share issuance, shareholder meetings, voting procedures, and other governance matters. It references relevant laws and regulatory bodies such as the China Securities Regulatory Commission and Beijing Stock Exchange rules. The content is a comprehensive governance document outlining internal rules and procedures rather than a financial report, announcement, or meeting minutes. Therefore, it fits the category of Governance Information (CGR). The document length is substantial and contains detailed governance rules, not just an announcement or summary, so it is not an RPA or RNS. Hence, the classification is CGR with high confidence.
2025-07-03 Chinese
独立董事候选人声明与承诺（杨娥）
Board/Management Information Classification · 95% confidence The document is a statement and commitment by an independent director candidate for Zhejiang Haisheng Pharmaceutical Co., Ltd. It details the candidate's qualifications, independence, and compliance with relevant laws and regulations. There is no financial data, no report or announcement of financial results, no voting results, no management changes, and no other regulatory filings typical of financial or corporate event reports. The document is a declaration related to board/management information, specifically about an independent director candidate's qualifications and commitments. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is 2683 characters, which is consistent with a detailed declaration rather than a full report or announcement.
2025-07-03 Chinese

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.